The EU Home Affairs Sub-Committee has written to Rt Hon Matt Hancock MP, in response to a letter received on the Government's preparations for access to medicines in the event of a 'no deal' Brexit.
The Sub-Committee initially wrote to Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care on 22 November 2018 following an evidence session with witnesses from the Nuffield Trust, British Association of European Pharmaceutical Distributors and law firm Maitland Walker LLP. The letter asked what work the Government had undertaken to ensure there would be no disruption to the supply of medicines and medical products in the event of the UK leaving the EU without a deal. Since this time, the Government has published several letters from the Secretary of State to medical suppliers and health care providers to update them on 'no deal' preparations.
The Minister of State for Health responded to the Committee's letter on 10 January 2019 and the Committee is now writing again to the Health Secretary on several outstanding areas of concern, including:
- When the Government will contact suppliers of medicines and medical products to give them notice and guidance on rerouting their supplies.
- Clarifying what affect a 'no deal' scenario may have on UK pharmaceutical manufacturers who supply within the UK.
- The agreements needed to allow organ exchange to continue after 29 March 2019, and how these will be concluded.
- The impact of a 'no-deal' scenario on clinical trials in progress on 29 March 2019, including the EU’s policy on clinical trials in the event of 'no deal' and what assurances the Government is providing to drug companies to encourage them to continue making their trials open for UK patients.
Image: Parliamentary Copyright